A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
Latest Information Update: 05 Jan 2024
At a glance
- Drugs Prexasertib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 30 Sep 2022 Results assessing ORR across cohort 3-4 published in the Gynecologic Oncology
- 05 Jul 2021 Status changed from active, no longer recruiting to completed.
- 01 Mar 2021 This trial has been completed in Belgium, according to Eudra record.